CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid produ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: King, Lisa A., Lameris, Roeland, de Gruijl, Tanja D., van der Vliet, Hans J.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2018
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6036112/
https://ncbi.nlm.nih.gov/pubmed/30013569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01519
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars